Compare GSK plc (GSK) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hershey Co — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while Hershey Co trades at $183 (market cap $36.56B). The key difference: GSK plc is far larger — about 2.8× Hershey Co's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | HSY | |
|---|---|---|
Market Cap | $102.60B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $236.28 |
52-Week Low | $38.22 | $162.31 |
Enterprise Value | $123.04B | $41.70B |
Dividend Yield | 3.57% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Hershey (HSY) trades at $184.19, up 0.79% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth remains steady at $11.69 billion for 2025. Technical indicators show bullish momentum with the current price near resistance at $184, supported by positive moving average signals. The company maintains robust profitability with 38.38% gross margins and 32.81% ROE, though net income declined to $883 million in 2025 from previous highs.
HSY presents a favorable risk-reward profile with analyst consensus target of $196.78 offering 7% upside potential. Recent margin recovery from favorable cocoa contracts and dividend growth support bullish sentiment, though volume declines and competitive pressures in salty snacks remain concerns. With 68.57% of analysts maintaining Hold ratings, the stock offers steady growth potential but requires monitoring of consumer demand trends and input cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
